dexamethasone 21-methanesulfonate: RN given refers to (11beta,16alpha)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 63041 |
| CHEMBL ID | 3967952 |
| SCHEMBL ID | 332913 |
| MeSH ID | M0099444 |
| Synonym |
|---|
| dexamethasone 21-mesylate |
| 2265-22-7 |
| dexamethasone 21-methanesulfonate |
| [2-[(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] methanesulfonate |
| pregna-1,4-diene-3,20-dione, 9-fluoro-11,17-dihydroxy-16-methyl-21-((methylsulfonyl)oxy)-, (11beta,16alpha)- |
| unii-o9s11fma79 |
| o9s11fma79 , |
| pregna-1,4-diene-3,20-dione, 9-fluoro-11,17-dihydroxy-16-methyl-21-((methylsulfonyl)oxy)-, (11.beta.,16.alpha.)- |
| SCHEMBL332913 |
| CHEMBL3967952 |
| 9-fluoro-11,17-dihydroxy-16-methyl-3,20-dioxopregna-1,4-dien-21-yl methanesulfonate |
| DTXSID60945322 |
| Q27285529 |
| [2-[(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl]methanesulfonate |
| Excerpt | Relevance | Reference |
|---|---|---|
| " These increases were relatively insensitive to the concentration of reporter gene, suggesting the titration of some transcription factor(s) involved in regulating the position of the glucocorticoid dose-response curve and the agonist activity of an antiglucocorticoid." | ( Induction properties of a transiently transfected glucocorticoid-responsive gene vary with glucocorticoid receptor concentration. Simons, SS; Szapary, D; Xu, M, 1996) | 0.29 |
| " Because GR and coregulator concentrations simultaneously altered the position of the physiologically relevant dose-response curve, and associated EC(50), of GR-agonist complexes, we also examined this phenomenon with PR." | ( New antiprogestins with partial agonist activity: potential selective progesterone receptor modulators (SPRMs) and probes for receptor- and coregulator-induced changes in progesterone receptor induction properties. Giannoukos, G; Meeker, JE; Simons, SS; Smith, CL; Szapary, D, 2001) | 0.31 |
| "Recent reports describe the ability of factors to modulate the position of the dose-response curve of receptor-agonist complexes, and the amount of partial agonist activity of receptor-antagonist complexes, of androgen, glucocorticoid (GRs), and progesterone receptors (PRs)." | ( Modulation of transcriptional sensitivity of mineralocorticoid and estrogen receptors. Anzick, S; Meltzer, P; Richter, WF; Simons, SS; Wang, Q, 2004) | 0.32 |
| "Varying the concentration of selected factors alters the induction properties of steroid receptors by changing the position of the dose-response curve (or the value for half-maximal induction=EC(50)) and the amount of partial agonist activity of antisteroids." | ( Effects of acetylation, polymerase phosphorylation, and DNA unwinding in glucocorticoid receptor transactivation. Chow, C; Kim, Y; Pommier, YG; Simons, SS; Sun, Y, 2006) | 0.33 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1316586 | Displacement of [3H]-dexamethasone from GR receptor in human IM-9 cytosolic extracts at 100 nM preincubated for 6 hrs followed by washout and second incubation with [3H]-dexamethasone for 4 hrs relative to control | 2016 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20 | Novel selective glucocorticoid receptor agonists (SEGRAs) with a covalent warhead for long-lasting inhibition. |
| AID1316598 | Displacement of [3H]-dexamethasone from GR receptor in human IM-9 cytosolic extracts using buffer solution without beta-mercaptoethanol at 100 nM preincubated for 6 hrs followed by washout and second incubation with [3H]-dexamethasone for 2 hrs relative t | 2016 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20 | Novel selective glucocorticoid receptor agonists (SEGRAs) with a covalent warhead for long-lasting inhibition. |
| AID1316590 | Displacement of [3H]-dexamethasone from GR receptor in human IM-9 cytosolic extracts at 100 nM preincubated for 6 hrs followed by [3H]-dexamethasone addition relative to control | 2016 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20 | Novel selective glucocorticoid receptor agonists (SEGRAs) with a covalent warhead for long-lasting inhibition. |
| AID1316597 | Displacement of [3H]-dexamethasone from GR receptor in human IM-9 cytosolic extracts using buffer solution without beta-mercaptoethanol at 100 nM preincubated for 6 hrs followed by washout and second incubation with [3H]-dexamethasone for 1 hr relative to | 2016 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20 | Novel selective glucocorticoid receptor agonists (SEGRAs) with a covalent warhead for long-lasting inhibition. |
| AID1316602 | Displacement of [3H]-dexamethasone from GR receptor in human IM-9 cytosolic extracts using buffer solution without beta-mercaptoethanol at 100 nM preincubated for 6 hrs followed by washout and second incubation with [3H]-dexamethasone for 24 hrs relative | 2016 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20 | Novel selective glucocorticoid receptor agonists (SEGRAs) with a covalent warhead for long-lasting inhibition. |
| AID1316587 | Displacement of [3H]-dexamethasone from GR receptor in human IM-9 cytosolic extracts at 100 nM preincubated for 6 hrs followed by washout and second incubation with [3H]-dexamethasone for 16 hrs relative to control | 2016 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20 | Novel selective glucocorticoid receptor agonists (SEGRAs) with a covalent warhead for long-lasting inhibition. |
| AID1316588 | Displacement of [3H]-dexamethasone from GR receptor in human IM-9 cytosolic extracts at 100 nM preincubated for 6 hrs followed by washout and second incubation with [3H]-dexamethasone for 24 hrs relative to control | 2016 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20 | Novel selective glucocorticoid receptor agonists (SEGRAs) with a covalent warhead for long-lasting inhibition. |
| AID1316583 | Displacement of [3H]-dexamethasone from GR receptor in human IM-9 cytosolic extracts at 100 nM preincubated for 6 hrs followed by washout and second incubation with [3H]-dexamethasone for 1 hr relative to control | 2016 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20 | Novel selective glucocorticoid receptor agonists (SEGRAs) with a covalent warhead for long-lasting inhibition. |
| AID1316599 | Displacement of [3H]-dexamethasone from GR receptor in human IM-9 cytosolic extracts using buffer solution without beta-mercaptoethanol at 100 nM preincubated for 6 hrs followed by washout and second incubation with [3H]-dexamethasone for 3 hrs relative t | 2016 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20 | Novel selective glucocorticoid receptor agonists (SEGRAs) with a covalent warhead for long-lasting inhibition. |
| AID1316584 | Displacement of [3H]-dexamethasone from GR receptor in human IM-9 cytosolic extracts at 100 nM preincubated for 6 hrs followed by washout and second incubation with [3H]-dexamethasone for 2 hrs relative to control | 2016 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20 | Novel selective glucocorticoid receptor agonists (SEGRAs) with a covalent warhead for long-lasting inhibition. |
| AID1316604 | Displacement of [3H]-dexamethasone from GR receptor in human IM-9 cytosolic extracts using buffer solution without beta-mercaptoethanol at 100 nM preincubated for 6 hrs followed by [3H]-dexamethasone addition relative to control | 2016 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20 | Novel selective glucocorticoid receptor agonists (SEGRAs) with a covalent warhead for long-lasting inhibition. |
| AID1316601 | Displacement of [3H]-dexamethasone from GR receptor in human IM-9 cytosolic extracts using buffer solution without beta-mercaptoethanol at 100 nM preincubated for 6 hrs followed by washout and second incubation with [3H]-dexamethasone for 16 hrs relative | 2016 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20 | Novel selective glucocorticoid receptor agonists (SEGRAs) with a covalent warhead for long-lasting inhibition. |
| AID1316600 | Displacement of [3H]-dexamethasone from GR receptor in human IM-9 cytosolic extracts using buffer solution without beta-mercaptoethanol at 100 nM preincubated for 6 hrs followed by washout and second incubation with [3H]-dexamethasone for 4 hrs relative t | 2016 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20 | Novel selective glucocorticoid receptor agonists (SEGRAs) with a covalent warhead for long-lasting inhibition. |
| AID1316585 | Displacement of [3H]-dexamethasone from GR receptor in human IM-9 cytosolic extracts at 100 nM preincubated for 6 hrs followed by washout and second incubation with [3H]-dexamethasone for 3 hrs relative to control | 2016 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20 | Novel selective glucocorticoid receptor agonists (SEGRAs) with a covalent warhead for long-lasting inhibition. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 49 (59.76) | 18.7374 |
| 1990's | 22 (26.83) | 18.2507 |
| 2000's | 8 (9.76) | 29.6817 |
| 2010's | 3 (3.66) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (9.64) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 83 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||